Vitrakvi（larotrectinib）

[Indications of Vitrakvi(larotrectinib)]

Vitrakvi(larotrectinib) is suitable for the treatment of locally advanced or metastatic solid tumors in adults and children with NTRK gene fusion.

Please click here to download the instructions issued by VITRAKVI FDA (PDF version).

Vitrakvi(larotrectinib) is a broad-spectrum anticancer drug, It is suitable for a variety of cancers: acute myeloid leukemia, astrocytoma, low-grade glioma of brain, breast cancer, colorectal cancer, congenital mesoderm nephroma, gastrointestinal stromal tumor, glioblastoma multiforme, head and neck squamous cell carcinoma, intrahepatic cholangiocarcinoma, lung cancer, salivary gland-derived breast analog secretory carcinoma, melanoma, sarcoma, secretory breast cancer, thyroid cancer, etc., and the overall effective rate reaches an astonishing 75%. 53% of patients’ tumors have shrunk by more than 30%, so Vitrakvi(larotrectinib) is called a new generation of cancer medicine.

[Vitrakvi(larotrectinib) specification]

This product is a capsule with a specification of 25mg/100mg/60 capsules, and also an oral liquid with a specification of 20mg/mL.

[Vitrakvi(larotrectinib) administration method]

Vitrakvi(larotrectinib) varies in dosage and frequency depending on the type of cancer to be treated. Please consult your physician.

[Precautions for Vitrakvi(larotrectinib)]

Vitrakvi(larotrectinib), also known as LOXO-101, is a new anticancer drug jointly developed by Bayer Pharmaceutical Company of Germany and LOXO. It is the first TRK inhibitor in the world. The full name of TRK is “tropomyosin receptor kinase”, which is an important signal pathway for regulating cell communication and cancer development, and NTRK is its corresponding coding gene. When suffering from cancer, the NTRK gene will be controlled by cancer cells, which will cause the TRK signal channel to be out of the control of human body, thus promoting the progress of cancer. Therefore, as long as there is gene fusion of NTRK, Vitrakvi(larotrectinib) is applicable.

The most common adverse reactions of Vitrakvi(larotrectinib) are fatigue, nausea, dizziness, vomiting, elevated AST, cough, elevated ALT, constipation and diarrhea. Special attention should be paid to the adverse reactions of nervous system in the first three months of treatment, and the liver transaminase should be monitored during the treatment period.